Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and obesity. The company is committed to bringing scientific approaches to well-understood biological pathways to help patients defeat serious illness. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Corbus Pharmaceuticals Holdings, Inc. does
In the company’s own words
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and obesity. The company is committed to bringing scientific approaches to well-understood biological pathways to help patients defeat serious illness.
The company's primary pipeline consists of two lead candidates. CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4 expression on cancer cells, designed to deliver a cytotoxic payload of monomethyl auristatin E. Licensed from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023, CRB-701 is being evaluated in a Phase 1/2 clinical trial in the United States and Europe for advanced solid tumors including head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. The drug has received fast track designation from the FDA for relapsed or refractory metastatic cervical cancer and recurrent or metastatic head and neck squamous cell carcinoma. CRB-913 is a highly peripherally restricted oral small molecule CB1 receptor inverse agonist for obesity treatment, representing a distinct mechanism of action from GLP-1 therapies. The company completed a Phase 1a study in December 2025 and initiated a Phase 1b dose-range finding study in December 2025.
Corbus also maintains CRB-601, an anti-αvβ8 integrin monoclonal antibody for solid tumors, though the company has deprioritized this program. The company incurred research and development expenses of $70.1 million in 2025 compared to $32.2 million in 2024, reflecting increased investment in clinical development activities.
The company does not operate manufacturing facilities and relies on third-party contract manufacturing organizations and licensing partners for drug supply. Corbus maintains intellectual property protection through licensed patents and proprietary technology platforms, with patent protections for its candidates extending through 2042 to 2046 depending on the program.
More information about Corbus Pharmaceuticals is available at www.corbuspharma.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NORWOOD, MA
- Fiscal year end
- December
- CIK
- 1595097
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Corbus Pharmaceuticals Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Corbus Pharmaceuticals Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Corbus Pharmaceuticals Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Corbus Pharmaceuticals Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Corbus Pharmaceuticals Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”